US State Disparities in Colorectal Cancer Rates
the Cancer Therapy Advisor take:
Greater progress in reducing colorectal cancer (CRC) incidence and mortality rates was observed in Northeastern states compared to Southern states, according to an article published online in the journal Cancer.
In this study, the investigators aimed to quantify disparities in CRC rates between Louisiana (representing Southern states) and New Jersey (representing Northeastern states) if differences in risk factors, screening, and stage-specific CRC survival were eliminated.
The Microsimulation Screening Analysis Colon microsimulation model estimated age-adjusted CRC incidence and mortality rates in Louisiana (between 1995 and 2009) under four assumptions: that residents in both states had the same smoking and obesity prevalence; CRC screening rates; stage-specific CRC relative survival ; and that the previous three assumptions were true.
Results showed the CRC incidence rate in Louisiana decreased by 3.5% when it had the same risk factors as New Jersey, and by 15.2% when it had the same screening rate as New Jersey.
If Louisiana had New Jersey’s risk factors, screening, and survival rates, the CRC mortality rate would be reduced by 3.0%, 10.8%, and 17.4%, respectively.
The modeled rates per 100,000 individuals in Louisiana had a greater reduction than the rates observed in New Jersey for both CRC incidence and mortality rates (116.4 vs. 130.0 and 44.7 vs. 55.8, respectively).
The study suggests that the differences in poor outcomes between Southern states and Northern states could be reduced if Southern states could achieve the same levels of screening, survival, and risk factors as those of Northern states.
Greater progress in reducing colorectal cancer incidence, mortality rates observed in Northeastern states compared to Southern states.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?
- NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms
- Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration
- Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma